The clinicians in the Neuroendocrine Tumor Clinical Program at City of Hope Chicago have extensive experience in diagnosing and treating neuroendocrine tumors (NETs), sometimes known as carcinoid tumors. Our doctors work with referring physicians and their patients to help treat and manage this rare disease, which develops when abnormal growths begin to form in neuroendocrine cells. NETs are staged using diagnostics including NETSPOT, an imaging agent that helps locate somatostatin receptor-positive NETs and determine treatment options. Our cancer experts then collaborate with one another, and with the patient, as part of a multidisciplinary team, to develop a personalized treatment plan tailored to each patient’s individual needs.
The NET Clinical Program provides patients a comprehensive array of treatment options. The type, location and extent of the disease dictate which treatments may be available.
Treatment options may include:
Peptide receptor radionuclide therapy combines a cell-targeting protein (or peptide) with a radionuclide (or radioactive material), and is given intravenously to deliver a high dose of radiation to the tumors.
Because of the complexity and diversity of NETs, our experts collaborate daily, allowing them to recommend a personalized care plan.
Depending on each patient’s unique diagnosis and needs, members of the NET care team may include surgical, medical or radiation oncologists, gastroenterologists, interventional radiologists, endocrinologists, pathologists, pain management physicians, dietitians, naturopathic oncology providers, mind-body therapists and other trained clinicians.